Analysis Tools
mortality/aging
|
• female mice die by 100 weeks of age
|
immune system
|
• female mice exhibit a slight increase in spleen weight to body weight compared with wild-type mice
|
|
• at 60 weeks, female mice exhibit a decrease in CD4+CD8- T cells in the spleen compared with wild-type mice
|
|
• at 60 weeks, female mice exhibit a decrease in CD4+CD8- T cells in the spleen compared with wild-type mice
|
|
• at 60 weeks in female mice
|
|
• at 60 weeks in female mice
|
|
• bleomycin-treated mice exhibit increased proliferation of alveolar macrophages compared with similarly treated wild-type mice
|
|
• rare in female mice
|
|
• in female mice
|
|
• at 60 weeks in female mice
|
|
• at 60 weeks of age, female mice exhibit severe glomerular lesions unlike wild-type mice
• female mice develop glomerulonephritis unlike wild-type mice
• female mice exhibit severe nephritis with interstitial inflammation unlike wild-type mice
• however, male mice do not exhibit nephritis
|
|
• bleomycin-treated mice exhibit increased lung inflammation with increased lymphocyte, neutrophils, and epithalial cell counts in bronchoalveolar lavage fluid and lung damage compared with similarly treated wild-type mice
|
renal/urinary system
|
• at 60 weeks, female mice exhibit lobular formation and moderate to severe cellular proliferation compared with wild-type mice
|
|
• at 60 weeks in female mice
|
|
• in female mice
|
|
• female mice exhibit subepithelial electron-dense deposits unlike wild-type mice
• female mice exhibit a collapsed glomerulus unlike wild-type mice
|
|
• female mice exhibit IgG, IgM, and C3 depositions and faint IgA depositions in the capillary walls of the glomeruli unlike in wild-type mice
|
|
• at 60 weeks of age, female mice exhibit severe glomerular lesions unlike wild-type mice
• female mice develop glomerulonephritis unlike wild-type mice
• female mice exhibit severe nephritis with interstitial inflammation unlike wild-type mice
• however, male mice do not exhibit nephritis
|
|
• female mice exhibit IgG and IgM deposits in mesangial regions unlike in wild-type mice
|
|
• 50-week-old female mice exhibit moderate mesangial proliferation with cellular crescents unlike wild-type mice
|
|
• female mice exhibit cellular proliferation and segmental sclerosis with a circumferential fibrocellular crescent and a collapsed glomerulus unlike wild-type mice
|
|
• at 60 weeks of age, female mice exhibit glomerular crescent formation
|
homeostasis/metabolism
|
• at 60 weeks in female mice
|
|
• in female mice
|
|
• oltipraz-treated mice fail to exhibit a reduction in tumor formation unlike similarly treated wild-type mice
(J:68072)
• bleomycin-treated mice exhibit increased weight loss, lung to body weight, total cell, lymphocyte, neutrophils, and epithalial cell counts in bronchoalveolar lavage fluid, lung fibrosis, lung inflammation, lung damage, and cell proliferation in terminal bronchioles and alveolar bronchiolization regions around fibroproliferative foci, alveolar macrophages, type 2 cells, bronchial basal cells, and endothelium compared with similarly treated wild-type mice
(J:118068)
|
|
• regardless of oltipaz-treatment, mice exposed to benzo[a]pyrene are more susceptible to neoplasia formation in the forestomach compared with similarly treated wild-type mice
|
cellular
|
• 50-week-old female mice exhibit moderate mesangial proliferation with cellular crescents unlike wild-type mice
|
|
• at 60 weeks, female mice exhibit lobular formation and moderate to severe cellular proliferation compared with wild-type mice
|
|
• female mice exhibit an increase in lipid peroxidation compared with wild-type mice
|
hematopoietic system
| N |
• mice exhibit normal hematocrit
|
|
• female mice exhibit a slight increase in spleen weight to body weight compared with wild-type mice
|
|
• at 60 weeks, female mice exhibit a decrease in CD4+CD8- T cells in the spleen compared with wild-type mice
|
|
• at 60 weeks, female mice exhibit a decrease in CD4+CD8- T cells in the spleen compared with wild-type mice
|
|
• at 60 weeks in female mice
|
|
• at 60 weeks in female mice
|
|
• bleomycin-treated mice exhibit increased proliferation of alveolar macrophages compared with similarly treated wild-type mice
|
neoplasm
|
• regardless of oltipaz-treatment, mice exposed to benzo[a]pyrene are more susceptible to neoplasia formation in the forestomach compared with similarly treated wild-type mice
|
|
• regardless of oltipaz-treatment, mice exposed to benzo[a]pyrene are more susceptible to neoplasia formation in the forestomach compared with similarly treated wild-type mice
|
growth/size/body
weight loss
(
J:118068
)
|
• in bleomycin-treated mice compared with similarly treated wild-type mice
|
|
• in bleomycin-treated mice compared with similarly treated wild-type mice
|
|
• female mice exhibit a slight increase in spleen weight to body weight compared with wild-type mice
|
respiratory system
|
• in bleomycin-treated mice compared with similarly treated wild-type mice
|
|
• bleomycin-treated mice exhibit increased proliferation of cells in terminal bronchioles and alveolar bronchiolization regions around fibroproliferative foci, alveolar macrophages, type 2 cells, bronchial basal cells, and endothelium compared with similarly treated wild-type mice
|
|
• bleomycin-treated mice exhibit increased lung inflammation with increased lymphocyte, neutrophils, and epithalial cell counts in bronchoalveolar lavage fluid and lung damage compared with similarly treated wild-type mice
|
cardiovascular system
|
• female mice exhibit IgG, IgM, and C3 depositions and faint IgA depositions in the capillary walls of the glomeruli unlike in wild-type mice
|
digestive/alimentary system
|
• regardless of oltipaz-treatment, mice exposed to benzo[a]pyrene are more susceptible to neoplasia formation in the forestomach compared with similarly treated wild-type mice
|
